Jepsen JS - Search Results

1

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator.

Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Juncker-Jensen A, et al. Among authors: jepsen js. Growth Horm IGF Res. 2006 Aug;16(4):224-39. doi: 10.1016/j.ghir.2006.06.005. Epub 2006 Aug 8. Growth Horm IGF Res. 2006. PMID: 16893667

2

Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.

Christensen GL, Jepsen JS, Fog CK, Christensen IJ, Lykkesfeldt AE. Christensen GL, et al. Among authors: jepsen js. Breast Cancer Res Treat. 2004 May;85(1):53-63. doi: 10.1023/B:BREA.0000021047.37869.95. Breast Cancer Res Treat. 2004. PMID: 15039597

3

Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.

Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Frogne T, et al. Among authors: jepsen js. Endocr Relat Cancer. 2005 Sep;12(3):599-614. doi: 10.1677/erc.1.00946. Endocr Relat Cancer. 2005. PMID: 16172194

4

Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA).

Jepsen JS, Pfundheller HM, Lykkesfeldt AE. Jepsen JS, et al. Oligonucleotides. 2004;14(2):147-56. doi: 10.1089/1545457041526281. Oligonucleotides. 2004. PMID: 15294077

5

Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.

Jepsen JS, Sørensen MD, Wengel J. Jepsen JS, et al. Oligonucleotides. 2004;14(2):130-46. doi: 10.1089/1545457041526317. Oligonucleotides. 2004. PMID: 15294076 Review.

6

LNA-antisense rivals siRNA for gene silencing.

Jepsen JS, Wengel J. Jepsen JS, et al. Curr Opin Drug Discov Devel. 2004 Mar;7(2):188-94. Curr Opin Drug Discov Devel. 2004. PMID: 15603252 Review.

7

Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).

Hrdlicka PJ, Andersen NK, Jepsen JS, Hansen FG, Haselmann KF, Nielsen C, Wengel J. Hrdlicka PJ, et al. Among authors: jepsen js. Bioorg Med Chem. 2005 Apr 1;13(7):2597-621. doi: 10.1016/j.bmc.2005.01.029. Bioorg Med Chem. 2005. PMID: 15755661

8

Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd).

Hrdlicka PJ, Jepsen JS, Wengel J. Hrdlicka PJ, et al. Among authors: jepsen js. Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):397-400. doi: 10.1081/ncn-200059821. Nucleosides Nucleotides Nucleic Acids. 2005. PMID: 16247958

9

Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA).

Vollmer J, Jepsen JS, Uhlmann E, Schetter C, Jurk M, Wader T, Wüllner M, Krieg AM. Vollmer J, et al. Among authors: jepsen js. Oligonucleotides. 2004 Spring;14(1):23-31. doi: 10.1089/154545704322988021. Oligonucleotides. 2004. PMID: 15104893

10

Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).

Hrdlicka PJ, Jepsen JS, Nielsen C, Wengel J. Hrdlicka PJ, et al. Among authors: jepsen js. Bioorg Med Chem. 2005 Feb 15;13(4):1249-60. doi: 10.1016/j.bmc.2004.11.054. Bioorg Med Chem. 2005. PMID: 15670934

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters